Overview

A Study to Evaluate Effects of Proton-pump Inhibitor on Acalabrutinib Capsule When Administered Orally With COCA-COLA in Healthy Participants

Status:
Completed

Trial end date:
2020-08-28

Target enrollment:

Participant gender:

Summary

This study is being conducted to support the clinical development of acalabrutinib in participants who need treatment with proton pump inhibitors while taking acalabrutinib.

Phase:

Phase 1

Details

Lead Sponsor:

AstraZeneca

Collaborators:

Acerta Pharma B.V.
Acerta Pharma BV

Treatments:

Acalabrutinib
Rabeprazole